Insider Trading Activity Global Blood Therapeutics, Inc. (NASDAQ:GBT) – Director Sold 27,053 shares of Stock

ME Staff
-
0

Insider Trading Activity For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Deval L Patrick , Director of Global Blood Therapeutics, Inc. (NASDAQ:GBT) reportedly Sold 27,053 shares of the company’s stock at an average price of 29.69 for a total transaction amount of $803,203.57 SEC Form

Insider Trading History For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

  • On 12/22/2015 Eleanor Ramos, insider, bought 11,000 with an average share price of $20.93 per share and the total transaction amounting to $230,230.00.View SEC Filing
  • On 1/7/2016 John Schembri, insider, bought 1,500 with an average share price of $21.57 per share and the total transaction amounting to $32,355.00.View SEC Filing
  • On 12/16/2016 Kevin P Starr, Major Shareholder, sold 108,955 with an average share price of $16.00 per share and the total transaction amounting to $1,743,280.00.View SEC Filing
  • On 4/6/2017 Robert I Tepper, Major Shareholder, sold 31,225 with an average share price of $33.23 per share and the total transaction amounting to $1,037,606.75.View SEC Filing
  • On 7/21/2017 Jung Choi, Insider, sold 3,000 with an average share price of $30.00 per share and the total transaction amounting to $90,000.00.View SEC Filing
  • On 7/25/2017 Deval L Patrick, Director, sold 27,053 with an average share price of $29.69 per share and the total transaction amounting to $803,203.57.View SEC Filing

    • Analyst Ratings For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
    These are 11 Buy Ratings .
    The current consensus rating for Global Blood Therapeutics, Inc. (NASDAQ:GBT) is Buy (Score: 3.00) with a consensus target price of $53.61 , a potential (98.54% upside)

    Analyst Ratings History For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

      with a price target of $43.00 to $26.00

    • On 9/30/2016 Wells Fargo & Company Initiated Coverage of rating Outperform with a price target of $75.00 to $23.05
    • On 12/5/2016 Cowen and Company Reiterated Rating Buy
    • On 3/1/2017 Nomura Initiated Coverage of rating Buy
    • On 3/1/2017 Instinet Initiated Coverage of rating Buy to Buy with a price target of $50.00
    • On 3/15/2017 J P Morgan Chase & Co Reiterated Rating Buy with a price target of $44.00
    • On 3/15/2017 Cantor Fitzgerald Initiated Coverage of rating Overweight to Overweight with a price target of $61.00

    Recent Trading Activity for Global Blood Therapeutics, Inc. (NASDAQ:GBT)
    Shares of Global Blood Therapeutics, Inc. closed the previous trading session at 27.00 down -0.90 -3.23% with 697,184 shares trading hands.